| 4 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
| 5.8M |
| $223.7M |
| +275.5% |
| 2.813% |
| 0.97% |
| 5 | BAKER BROS. ADVISORS LP | 5.4M | $209.4M | -0.4% | 2.633% | 1.05% |
| 6 | STATE STREET CORP | 4.6M | $177.9M | +1.7% | 2.237% | 0.00% |
| 7 | MORGAN STANLEY | 4.5M | $174.7M | +17.0% | 2.197% | 0.01% |
| 8 | TCG Crossover Management, LLC | 4.5M | $171.8M | 0.0% | 2.160% | 4.13% |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9M | $150.7M | +5.5% | 1.895% | 0.01% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6M | $140.2M | +0.5% | 1.763% | 0.00% |
| 11 | JENNISON ASSOCIATES LLC | 3.3M | $127.5M | +3.5% | 1.604% | 0.08% |
| 12 | RTW INVESTMENTS, LP | 3.2M | $122.4M | 0.0% | 1.540% | 1.05% |
| 13 | Two Seas Capital LP | 3.1M | $121.3M | -1.7% | 1.525% | 2.40% |
| 14 | ARMISTICE CAPITAL, LLC | 2.9M | $113.1M | -46.3% | 1.422% | 1.38% |
| 15 | ADAR1 Capital Management, LLC | 2.3M | $89.8M | -13.0% | 1.129% | 4.11% |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 2.2M | $86.1M | +6.8% | 1.083% | 0.00% |
| 17 | Woodline Partners LP | 2.0M | $76.1M | 0.0% | 0.957% | 0.24% |
| 18 | GOLDMAN SACHS GROUP INC | 1.8M | $67.5M | -1.9% | 0.848% | 0.01% |
| 19 | Alpine Global Management, LLC | 1.4M | $53.0M | -47.9% | 0.666% | 8.61% |
| 20 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.4M | $52.7M | +12.4% | 0.663% | 0.00% |
| 21 | PERCEPTIVE ADVISORS LLC | 1.4M | $52.3M | -15.0% | 0.658% | 0.79% |
| 22 | D. E. Shaw & Co., Inc. | 1.2M | $47.8M | — | 0.601% | 0.02% |
| 23 | BANK OF AMERICA CORP /DE/ | 1.2M | $45.5M | +32.2% | 0.572% | 0.00% |
| 24 | Aberdeen Group plc | 857K | $33.0M | -26.2% | 0.415% | 0.05% |
| 25 | NORTHERN TRUST CORP | 794K | $30.6M | +18.0% | 0.385% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in IMVT — a direct measure of their conviction.
| 55.86% |
| +1.21 pp |
| $1.51B |
| 18% |
| Q4 2024 | 183 | +1.7% | 54.65% | +0.72 pp | $1.83B | 13% |
| Q3 2024 | 180 | — | 53.93% | — | $2.10B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
IMVT institutional ownership fell by 1.08 percentage points quarter-over-quarter, with a net change of +12 holders.
The top 10 institutions account for 60.4% of all reported 13F value in IMVT, and the top 25 account for 87.4%.
Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.